Core Insights - Xellar Biosystems has recently completed a strategic financing round of several tens of millions, led by Jingtai Technology, with existing investors TianTu Investment and Yayi Capital increasing their stakes [1] - The funds will be used to accelerate the construction of the "3D-Wet-AI" closed-loop system and expand international cooperation and commercialization [1] - The FDA's recent announcement to gradually eliminate mandatory animal testing for monoclonal antibody therapies represents a significant milestone for organoid and organ-on-chip companies [1] Company Overview - Founded at the end of 2021, Xellar Biosystems focuses on developing high-throughput organ chips and AI model platforms to assist in core processes of new drug development, including clinical research and safety evaluation [1][2] - The company has participated in the OASIS Consortium, which supports the development of next-generation clinical drug toxicity prediction tools [2] - Xellar's EPIC™ technology platform integrates microfluidic chip technology, disease organ modeling, high-throughput experimental systems, and generative AI algorithms to enhance drug development processes [2] Market and Industry Trends - Major pharmaceutical companies are increasingly interested in organoid and organ-on-chip technologies to reduce drug screening costs and improve predictive accuracy through AI [2] - The combination of AI and organ chips is seen as a potential revolution in traditional drug development methods, with the industry anticipating a positive shift following the FDA's new policies [1][3] - There are mixed market reactions, with some viewing the FDA's decision as irresponsible, while others see it as a concrete step towards integrating organoid technology with AI [1] Investor Perspectives - The CEO of Xellar, Dr. Xie Xin, emphasizes that the integration of AI and organ chips is not just a technological upgrade but a reconstruction of the entire research logic [3] - Jingtai Technology's chairman, Dr. Wen Shuhao, views Xellar as a strategic partner in the AI and organ chip space, aiming to create a sustainable, iterative new drug development system [3][4] - TianTu Investment highlights Xellar as a key technology platform company, noting its rapid iteration in chip design and organ modeling, as well as its collaboration with international pharmaceutical companies [3][4]
「耀速科技」获数千万元战略投资，推动“AI+器官芯片”助力新药研发新范式｜36氪首发
3 6 Ke·2025-04-28 00:31